share_log

Calliditas Therapeutics Reports Data From Phase 2 Study Of Setanaxib In Combination With Pembrolizumab For Head And Neck Cancer

カリディタスセラピューティクスは、SetanaxibとPembrolizumabの併用による頭頸部がんの第2相研究のデータを報告しています。

Benzinga ·  05/06 03:52

Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck (SCCHN). The analysis showed statistically significant improvements in progression-free survival (PFS), as well as in overall survival (OS), with statistically significant changes in tumor biology consistent with the mechanism of action of setanaxib.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする